June 27 Financial Quick Takes: Esperion gets $125M from Oberland in funding deal for cholesterol candidates; plus Woodford, PanTheryx and Castle

Esperion, Oberland strike funding deal ahead of bempedoic acid launch
Esperion Therapeutics Inc. (NASDAQ:ESPR) forged a funding agreement with Oberland Capital tied to revenues from the sale of products

Read the full 282 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE